Evidence map›Paper›PMID 26329972›Full record

ArticleOncotarget2015

Reduced rate of copy number aberrations in mucinous colorectal carcinoma.

Niek Hugen, Femke Simmer, Leonie J M Mekenkamp, Miriam Koopman, Evert van den Broek, Johannes H W de Wilt, Cornelis J A Punt, Bauke Ylstra, Gerrit A Meijer, Iris D Nagtegaal

Open access · diamondAbstract readComparative Study
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Niek HugenDepartment of Surgery, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands.
Femke SimmerDepartment of Pathology, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands.
Leonie J M MekenkampDepartment of Internal Medicine, Medical Spectrum Twente Enschede, 7500 KA Enschede, The Netherlands.
Miriam KoopmanDepartment of Medical Oncology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands.
Evert van den BroekDepartment of Pathology, VU University Medical Centre, 1007 MB Amsterdam, The Netherlands.
Johannes H W de WiltDepartment of Surgery, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands.
Cornelis J A PuntDepartment of Medical Oncology, Academic Medical Center University of Amsterdam, 1100 DD Amsterdam, The Netherlands.
Bauke YlstraDepartment of Pathology, VU University Medical Centre, 1007 MB Amsterdam, The Netherlands.
Gerrit A MeijerDepartment of Pathology, VU University Medical Centre, 1007 MB Amsterdam, The Netherlands.
Iris D NagtegaalDepartment of Pathology, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands.
Radboud University Nijmegen · NLAmsterdam UMC Location VUmc · NLMedisch Spectrum Twente · NLUniversity Medical Center Utrecht · NLUniversity of Amsterdam · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMucinous carcinoma (MC) is found in 10%-15% of colorectal cancer (CRC) patients. It differs from the common adenocarcinoma (AC) in histopathological appearance and clinical behavior.

methodsGenome-wide DNA copy number and survival data from MC and AC primary CRC samples from patients from two phase III trials (CAIRO and CAIRO2) was compared. Chromosomal copy number data from The Cancer Genome Atlas (TCGA) was used for validation. Altogether, 470 ACs were compared to 57 MCs.

resultsMC showed a reduced amount of copy number aberrations (CNAs) compared with AC for the CAIRO/CAIRO2 cohort, with a median amount of CNAs that was 1.5-fold lower (P = 0.002). Data from TCGA also showed a reduced amount of CNAs for MC. MC samples in both cohorts displayed less gain at chromosome 20q and less loss of chromosome 18p. A high rate of chromosomal instability was a strong negative prognostic marker for survival in MC patients from the CAIRO cohorts (hazard ratio 15.60, 95% CI 3.24-75.05).

conclusionsResults from this study indicate that the distinct MC phenotype is accompanied by a different genetic basis when compared with AC and show a strong association between the rate of chromosomal instability and survival in MC patients.

Indexed as

DNA Copy Number VariationsGene DosageAdenocarcinoma, MucinousBiomarkers, TumorChromosomal InstabilityChromosomes, Human, Pair 18Chromosomes, Human, Pair 20Clinical Trials, Phase III as TopicColorectal NeoplasmsDatabases, GeneticGenetic Predisposition to DiseaseHumansKaplan-Meier EstimatePhenotypeProportional Hazards ModelsRandomized Controlled Trials as TopicBiomarkers, Tumorcolorectal adenocarcinomacomparative genomic hybridizationcopy number profilemucinous carcinoma

Identifiers

PMID26329972
PMCPMC4694861
OpenAlexW1442570190

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.